Actelion retained at neutral by Merrill

Actelion Ltd. was maintained at its neutral rating by Merrill Lynch analyst Erica Whittaker. The analyst expects clinical results from the company's advanced pipeline product clazosentan to prevent vasospasm following subarachnoid hemorrhage which only affects a small number of patients. Merrill believes the potential sales opportunity could be between $250 million and $500 million. Shares of the Allschwil, Switzerland, biopharmaceutical company were down CHF2.80, or 1.96%, at CHF140.00. (EBS: ATLN SW)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.